Iambic Therapeutics Announces IPO; NVIDIA Holds 9.6M Shares
- Iambic Therapeutics announces IPO and NASDAQ listing under symbol IAM
- NVIDIA Corporation held 9.6 million shares prior to the offering
- Filing submitted to SEC on September 21, 2026
- Listing targeted at NASDAQ Global Select Market
*this image is generated using AI for illustrative purposes only.
Iambic Therapeutics announced its initial public offering of common stock and applied to list on the NASDAQ Global Select Market under the symbol IAM.
The filing reveals significant institutional interest ahead of the public listing, with NVIDIA Corporation holding a substantial stake in the biotechnology firm.
Key Filing Details
According to the SEC filing dated September 21, 2026, NVIDIA Corporation beneficially owned 9.6 million shares of Iambic Therapeutics prior to the offering.
| Entity | Shareholding | Status |
|---|---|---|
| NVIDIA Corporation | 9.6 million shares | Beneficial owner pre-offering |
The company’s decision to list on the NASDAQ Global Select Market signals its intent to raise capital and increase liquidity for existing shareholders. The filing does not disclose the final number of shares to be issued or the price range for the IPO.
How might NVIDIA's 9.6 million share stake influence Iambic Therapeutics' strategic direction toward AI-driven drug discovery?
What are the potential market reactions if NVIDIA exercises its lock-up expiration rights to sell shares post-IPO?
How will the capital raised from this NASDAQ listing be allocated between R&D pipelines and commercialization efforts?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
